The Rise of Peptides in Wellness and Fitness
In recent years, there has been a significant boom in the use of peptides for therapeutic purposes, driven by influencers and athletes who promote these substances for benefits such as injury repair, weight loss, anti-ageing, and mood enhancement. This trend has sparked interest and concern, leading to investigations by medicines watchdogs into UK peptide clinics over health claims.
What Exactly Are Peptides?
Peptides are short chains of amino acids that serve various functions in the body. Some occur naturally, like insulin, oxytocin, and vasopressin, which regulate blood sugar, social behaviours, and water retention. Others form when proteins break down during digestion. However, the current hype centres on synthetic peptides used for therapeutic goals, including approved prescription weight-loss medications such as semaglutide (found in Wegovy) and tirzepatide (found in Mounjaro).
Despite these regulated options, many peptides on the market are unregulated and experimental, sold for self-injection without undergoing strict regulatory processes.
Who Is Using Peptide Products?
Initially, peptides were a niche interest among powerlifters and bodybuilders in the 2010s, focusing on growth-hormone-releasing peptides like GHRP-2 and GHRP-6. According to Dr. Luke Turnock, a senior lecturer in criminology at the University of Lincoln, these were used for muscle growth, tissue repair, and to avoid post-steroid slumps. Today, interest has exploded, with high-profile figures like US podcaster Joe Rogan advocating peptides such as BPC-157 and TB-500, known as the "Wolverine stack," for injury recovery.
Other popular peptides include CJC-1295, MK-677, ipamorelin for muscle building, and GHK-Cu for anti-ageing effects. Social media is flooded with discussions on selling, buying, and injecting these substances, primarily among health and fitness enthusiasts.
Evidence and Safety Concerns
Academics highlight that most experimental peptides lack robust scientific evidence to support their claims. Studies often involve animals or cells, not humans. For instance, a recent US review noted that BPC-157 shows potential in tendon and muscle repair but remains unvalidated in human trials, with no randomised control trials. Similarly, TB-500 has shown signs of promoting blood vessel formation in preclinical studies, but human data are absent, and it is banned in sports by the World Anti-Doping Authority.
Key issues include unknown indications, dosing, frequency, and duration of treatment, raising significant safety concerns.
Legal and Regulatory Landscape
In the UK, many popular peptides are not classified as medicines, meaning they are unregulated by the Medicines and Healthcare products Regulatory Agency (MHRA). However, if sellers make medicinal claims, these products must hold marketing authorisation. Lynda Scammell, head of borderline products at the MHRA, emphasised that labelling peptides "for research purposes only" does not exempt them from scrutiny if intended for human use.
The MHRA can take action, including removing unauthorised products from the market, to ensure regulatory compliance.
Risks and Expert Warnings
Experts like Prof. Adam Taylor from Lancaster University warn of numerous risks associated with experimental, unregulated peptides. Potential benefits in preclinical studies do not guarantee safety or efficacy in humans. Concerns include product purity, contamination with dangerous ingredients or bacterial endotoxins, and disruption of natural bodily systems due to injected peptides.
Additionally, peptides involved in multiple pathways could have unexpected effects, and some are linked to tumour growth, posing cancer risks. Self-injection hazards, interactions with existing medications, and lack of active monitoring further compound the dangers, with long-term damage potentially going unnoticed.
As the peptide trend continues to grow, regulatory bodies and health experts urge caution, stressing the need for evidence-based approaches and stricter oversight to protect public health.
